Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Affiliations

• ¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
• ² Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
• ³ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
• ⁴ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
• ⁵ Emmes Corporation, Rockville, Maryland.
• ⁶ U.S. Food and Drug Administration, Silver Spring, Maryland.
• ⁷ Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
• ⁸ Department of Surgery, Division of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.
• ⁹ University of Hawaii Cancer Center, Honolulu, Hawaii.
• ¹⁰ Department of Biostatistics, Dana Farber Cancer Institute, Boston, Massachusetts.
• ¹¹ Division of Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
• ¹² Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom; University Hospitals of Leicester, Leicester, United Kingdom.
• ¹³ Department of Thoracic Surgery, University of Maryland Cancer Center, Baltimore, Maryland.
• ¹⁴ Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
• ¹⁵ Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
• ¹⁶ Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
• ¹⁷ Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
• ¹⁸ Mesothelioma Applied Research Foundation, Alexandria, Virginia.
• ¹⁹ University of Colorado Cancer Center, IASLC, Denver, Colorado.
• ²⁰ The Company of Biologists, Cambridge, United Kingdom.
• ²¹ Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
• ²² Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
• ²³ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
• ²⁴ Medical School, University of Western Australia, Perth, Western Australia, Australia; National Center for Asbestos Related Diseases, University of Western Australia, Perth, Western Australia, Australia.
• ²⁵ Department of Cardiothoracic Surgery, New York University, Langone Medical Center, New York, New York.
• ²⁶ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
• ²⁷ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
• ²⁸ National Centre for Asbestos Related Disease, University of Western Australia, Nedlands, Western Australia, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
• ²⁹ Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York.
• ³⁰ Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
• ³¹ Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
• ³² Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland.
• ³³ Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
• ³⁴ Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
• ³⁵ Department of Pathology, University of Toronto, Toronto, Ontario, Canada; Department of Pathology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Ontario, Canada.
• ³⁶ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
• ³⁷ Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: [email protected].